Skip to main content

Study of the effect of combined interferon and ribavirin therapy on the hearing profile of hepatitis C virus patients

En

Abstract

Objectives

This study aimed to study the effect of combined pegylated interferon and ribavirin (Peg-IFN/RBV) therapy on the hearing profile of patients with hepatitis C virus (HCV).

Materials and methods

The auditory system of a total of 74 chronic HCV patients was assessed using pure tone audiometry (conventional and high frequency) and distortion product otoacoustic emissions (DPOAEs in the form of a DP-gram) immediately before therapy and at the end of the 12th and 24th weeks. Vestibulocochlear adverse effects including hearing loss, tinnitus, vertigo, and otalgia were also considered.

Results

Significant elevations in hearing thresholds were found on comparing thresholds at the 12th and 24th weeks with those at the onset of the study. The elevations were mostly at higher frequencies (3000, 4000, 6000, 8000, 9000, 10 000, 11 200, and 12 500 Hz), and did not affect speech perception. For DPOAE, significant differences were observed at all F2 frequencies on comparing both amplitudes and signal to noise ratios at the 12th and 24th weeks with those before therapy, with significance appearing earlier for higher F2 frequencies. Otologic complaints were insignificant, except for tinnitus; a significant increase in tinnitus was observed from 0 to 31.1% by the end of the study.

Conclusion

Significant auditory adverse effects may result from combined Peg-IFN/RBV therapy in HCV patients, highlighting the importance of prompt monitoring of auditory functions in these patients.

References

  1. 1

    Patrick DM, Buxton JA, Bigham M, Mathias RG. Public health and hepatitis C. Can J Public Health 2000; 91: S18–S23.

    Article  Google Scholar 

  2. 2

    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061–1069.

    CAS  Article  Google Scholar 

  3. 3

    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 wk or for 24 wk versus interferon alpha 2b plus placebo for 48 wk for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426–1432.

    CAS  Article  Google Scholar 

  4. 4

    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485–1492.

    CAS  Article  Google Scholar 

  5. 5

    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958–965.

    CAS  Article  Google Scholar 

  6. 6

    Fried MW, Schiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975–982.

    CAS  Article  Google Scholar 

  7. 7

    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346–355.

    CAS  Article  Google Scholar 

  8. 8

    Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomized, double-blind, placebo-controlled trial of interferon alpha-2-b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83–87.

    CAS  Article  Google Scholar 

  9. 9

    Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, et al. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004; 99: 873–877.

    CAS  Article  Google Scholar 

  10. 10

    Wong VK, Cheong-Lee C, Ford JA, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy. World J Gastroenterol 2005; 11: 53923.

    Google Scholar 

  11. 11

    Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, et al. Sudden hearing loss associated with peg interferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol 2007; 13: 5411–5412.

    Article  Google Scholar 

  12. 12

    Kanda Y, Shigeno K, Matsuo H, Yano M, Yamada N, Kumagami H. Interferon induced hearing loss. Audiology 1995; 34: 98–102.

    CAS  Article  Google Scholar 

  13. 13

    Görür K, Kandemir Ö, Ünal M, Özcan C. The effect of recombinant interferon-alpha treatment on hearing thresholds in patients with chronic viral hepatitis B. Auris Nasus Larynx 2003; 30: 41–44.

    Article  Google Scholar 

  14. 14

    Toosi MN, Hassanabadi MS. Hearing loss as a complication of peginterferon-alpha 2a combination therapy in a patient with hepatitis C virus infection. Hepatitis Monthly 2004; 4: 79–82.

    Google Scholar 

  15. 15

    Piekarska A, Jozefowicz Korczynska M, Wojcik K, Berkan E. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin. Int J Audiol 2007; 46: 345–350.

    Article  Google Scholar 

  16. 16

    Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side-effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283–291.

    CAS  Article  Google Scholar 

  17. 17

    Shabana MI, Amer AR, Dabbous AO, Al-Sunni AA. Hearing profile in hepatitis C virus patients under dual treatment with interferon and ribavirin. Audiological Med 2010; 8: 142–153.

    Article  Google Scholar 

  18. 18

    Hagr A, Jamjoom D, Sanai FM, Alhamoudi W, Abdo AA, Alarfaj A. Effect of interferon treatment on hearing of patients with chronic hepatitis C. Saudi J Gastroenterol 2011; 17: 114–118.

    Article  Google Scholar 

  19. 19

    Khan MM, Tahrir M, Raza M, Bhatti MA, Khokar MR. Hepatitis ‘C’; association of interferon-ribavirin therapy with hearing loss. Professional Med J 2012; 19: 193–196.

    Google Scholar 

  20. 20

    Bisht M, Bist SS. Ototoxicity: the hidden menace. Indian J Otolaryngol Head Neck Surg 2011; 63: 255–259.

    Article  Google Scholar 

  21. 21

    Stavroulaki P, Apostolopoulos N, Dinopoulou D, Vossinakis I, Tsakanikos M, Douniadakis D. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 1999; 50: 177–184.

    CAS  Article  Google Scholar 

  22. 22

    Fausti SA, Henry JA, Schaffer HI, Olsen DJ, Frey RH, Bagby GC. High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg 1993; 119: 661–668.

    CAS  Article  Google Scholar 

  23. 23

    Soliman SM. Speech discrimination audiometry using Arabic phonetically-balanced words. Ain Shams Med J 1976; 27: 27–30.

    Google Scholar 

  24. 24

    Soliman SM, Fathalla A, Shehata M. Development of Arabic staggered spondee words. (SSW) test. Proceedings of 8th Ain Shams Med Congress; Ain Shams University, Cairo, Egypt, 1985. pp. 1220–1246.

    Google Scholar 

  25. 25

    Hall JW. Handbook of otoacoustic emissions. San Diego, CA: Singular Publishing Group; 2002.

    Google Scholar 

  26. 26

    Lange C, Sarrazin C. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Diagnostic tests in acute and chronic hepatitis C. The flying publisher short guide to hepatitis C. 2012 ed. Germany: Flying Publisher & Kamps; 2012. 28–33.

    Google Scholar 

  27. 27

    Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338–1345.

    CAS  Article  Google Scholar 

  28. 28

    Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821–827.

    CAS  Article  Google Scholar 

  29. 29

    Seligman H, Podoshin L, Ben-David J, Fradis M. Drug-induced tinnitus and other hearing disorders. Drug Saf 1996; 14: 198–212.

    Article  Google Scholar 

  30. 30

    Eser Karlidag G, Karlidag T, Demirdag K, Keles E. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B. Auris Nasus Larynx 2011; 38:312–318.

    Article  Google Scholar 

  31. 31

    Johnson K, Sargent LA, Galizio C, Ubogu EE. Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. Eur J Gastroenterol Hepatol 2008; 20: 1110–1114.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Samir Asal MD.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Conflicts of Interest

None declared.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Asal, S., Sobhy, O., Ismail, O. et al. Study of the effect of combined interferon and ribavirin therapy on the hearing profile of hepatitis C virus patients. Egypt J Otolaryngol 31, 237–243 (2015). https://doi.org/10.4103/1012-5574.168359

Download citation

Keywords

  • audiometry
  • distortion product otoacoustic emissions
  • hepatitis
  • interferon
  • ribavirin